The emergence of viral diseases, of which Influenza and COVID-19 are examples, threatens global health and global socio-economic stability. It is thus critical to rapidly respond with therapeutic strategies to tackle viral threads and outbreaks.
This project aims to develop an integrated platform (BioPlaTTAR) to respond to viral threads and outbreaks in a fast and efficient way, with a streamlined pipeline, ranging from lead generation to in vivo validation. This platform will accelerate the development of tailored biopharmaceuticals when they are most needed. BioPlaTTAR, funded by Fundación La Caixa and Fundação para a Ciência e Tecnologia, joins the global effort to pursue treatments for use, alternatively to or together with vaccines, and boost the competitiveness and self-sufficiency of Iberia and Europe in the field of biopharmaceutical development.
Company Details
- Address
- Itqb - Universidade Nova De Lisboa, Oeiras,portugal
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- CCDR Lisboa e Vale do Tejo.
- HQ
- Oeiras
Bioplattar Questions
Bioplattar's LinkedIn profile is https://pt.linkedin.com/company/bioplattar
Bioplattar's industry is
Biotechnology Research
Bioplattar's top competitors are
El Faro,
Evamobs,
Sne - Sindicato Nacional Dos Enfermeiros,
Lecturers Without Borders (Lewibo),
Sunstone Project Eu,
Fundación ”la Caixa”,
Ccdr Lisboa E Vale Do Tejo,
Erinha,
Kd Global Ltd,
Bluepharma.
Bioplattar's categories are Biotechnology Research
